10 results about "Fetuin" patented technology

Pharmaceutical compositions and methods of producing them are described. The pharmaceutical composition may include (A) a follistatin protein or a variant thereof, and (B) a fetuin A protein or a fragment or variant thereof, wherein (B) is capable of binding to TGF-β, and wherein the total amount of (A) and (B) is greater than 10% of total proteins in the composition. Methods of preparing a secretome composition may include culturing stem cells in a protein-free media comprising trehalose, harvesting supernatant from the sample and replacing the supernatant with a fresh protein-free media comprising trehalose, and combining the harvested supernatant to prepare the secretome composition.

The present disclosure relates to correlating the ratio of the determined level of fetal globulin A fragment to the determined level of urine creatinine to the likelihood of graft function deterioration in a recipient.

The invention provides an extraction method and application of bovine fetal globulin, and belongs to the technical field of bioactive protein extraction. According to the method, low-temperature (4-8 DEG C) enzymolysis is adopted, so that denaturation of bovine placenta globulin due to high temperature can be avoided, and the natural structure and activity of bovine placenta protein are reserved to the greatest extent; then, membranes with different pore diameters are used for separating and purifying the bovine fetal globulin extracting solution, so that the damage of chemical substances to the activity of the bovine fetal globulin is avoided, and the activity of the bovine fetal globulin is greatly kept; the purity of the bovine fetal globulin can be improved by adopting chromatographic purification; through freeze drying, the molecular structure of the bovine fetal globulin in a frozen state is fixed, so that the interaction and chemical reaction among molecules are reduced, and the denaturation and inactivation of the bovine fetal globulin are effectively prevented; through the synergistic effect of enzymolysis at low temperature, multi-stage membrane separation and freeze drying, the preparation of the bovine fetal globulin of which the activity retention rate is greater than 95% is realized.

The present invention discloses the application of an inhibitor of fetuin A in the medicament for treating alcoholic fatty liver. In order to explore the new mechanism of the progression of ASH and find new therapeutic targets, we constructed a mouse model of alcoholic steatohepatitis with reference to the NIAAA method and performed liver tissue expression profiling sequencing, and found and verified that fetuin-A was positively correlated with alcoholic liver injury, hepatic steatosis and inflammatory changes, and inhibiting the level of fetuin-A had a protective effect on mouse alcoholic steatohepatitis (see Figures 1 to 6). These will contribute to understanding the occurrence and development process of ASH from a new perspective, contribute to the development of targeted drugs for this disease, and are expected to prevent or delay or even contribute to the reversal of the early ALD course by improving lipid metabolism disorders and reducing injury responses.

The invention belongs to the technical field of assisted reproduction, and discloses an IVM serum-free culture solution based on fetuin. The IVM serum-free culture solution comprises the following components: an IVM serum-free culture basic solution, 0-10 mg / mL of non-typing fetuin, and the non-typing fetuin comprises fetuin-A (fetuin-A) and fetuin-B (fetuin-B), and the IVM serum-free culture basic solution comprises the IVM serum-free culture basic solution and the non-typing fetuin-A (fetuin-A) and the fetuin-B (fetuin-B), the IVM serum-free culture basic solution is prepared from 2.5 to 10 mM of sodium pyruvate, 5 mg / mL of human albumin, 10 ng / mL of epidermal growth factor (EGF), 0.075 IU / mL of follicle stimulating hormone (FSH), 0.075 IU / mL of human chorionic gonadotropin (hCG), an amino acid composition, vitamins and inorganic salt. Experiments show that by adopting the formula, the maturation rate of oocytes can reach 95.55% + / -0.51%, the natural fertilization rate can reach 90.68% + / -1.12%, the blastocyst rate can reach 85.02 + / -1.85%, the problems of cumulus expansion abnormity, zona pellucida sclerosis (ZP2 abnormal cutting), embryo morphology abnormity and the like in a serum-free system can be synchronously solved, the effect is superior to that of a single serum-B (10 [mu] g / mL) culture solution, a single serum-A (0.9 mg / mL) culture solution or a serum-containing culture solution, and serum pathogen risks and ICSI operation dependence are avoided.

The invention discloses an HSPC protection factor, application of the HSPC protection factor to preparation of a medicine for preventing children leukemia and a medicine composition. The HSPC protection factor is selected from at least one of fetal globulin-A, a Tlr4 agonist, a bZIP agonist and a Blm agonist with effective prevention dose. The HSPC protection factor protects the genome of the HSPC by activating at least one of Tlr4 / Myd88 / bZIP / Blm signal pathways, so that the HSPC is not easy to generate DNA double-strand breakage, the formation of leukemia initial mutation is effectively prevented, and the occurrence of children leukemia is prevented.

The present invention relates to Fetuin-A for use in a method for treating or preventing a pathological inflammation in a patient, wherein the patient is preferably characterized by having a blood serum level of Fetuin-A below a non-pathological blood serum level, and / or a blood serum level of tumor necrosis factor alpha (TNF-α) above the average blood serum level found in the healthy population.

The present disclosure relates to correlating the ratio of the determined level of fetal globulin A fragment to the determined level of urine creatinine to the likelihood of progressive renal function drop to the terminal point of the kidney in a subject over a period of time.

The present invention discloses a serum-free medium with defined components for culturing mesenchymal stem cells and its applications. The present invention discloses a serum-free medium with defined components for culturing mesenchymal stem cells. The components of the serum-free medium include a basal medium and L-glutamine, transferrin, L-ascorbic acid, lipid mixture, putrescine, human serum albumin, heparin sodium, progesterone, HEPES, fetuin, hydrocortisone, trimipramine, and insulin-like growth factor. The present invention provides the use of the aforementioned serum-free medium in culturing mesenchymal stem cells and its application in a system, device, or equipment for preparing a serum-free medium for automated production of mesenchymal stem cells. The serum-free medium of the present invention has defined components, can avoid the interference of serum on cell culture, and can effectively promote the in vitro expansion of mesenchymal stem cells, highlighting the outstanding culture advantages of the serum-free medium described in the present invention.

This invention discloses a serum-free proliferation medium for efficiently culturing porcine muscle stem cells, belonging to the field of cell culture technology. This serum-free proliferation medium is based on DMEM / F12 and contains ITS, L-ascorbic acid, BSA, Fetuin, FGF-2, and other components. This invention optimized the concentrations of key factors such as BSA, Fetuin, and FGF-2 through single-factor analysis, Plackett-Burman assays, and steepest ascent and Box-Behnken response surface methodology, successfully constructing a low-cost, green serum-free culture medium suitable for porcine muscle stem cells. The short-term culture effect of this serum-free medium on porcine muscle stem cells is comparable to that of complete culture media, with a significant cost advantage, laying the foundation for further long-term cell culture and functional maintenance under serum-free conditions.